Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245359 | 0.88 | PPARD (0.74) | PPARDPPARA | |
| SCHEMBL1745624 | 0.88 | PPARD (0.72) | PPARDPPARA | |
| SCHEMBL1745627 | 0.88 | PPARD (0.72) | PPARDPPARA | |
| SCHEMBL12909669 | 0.86 | PPARD (0.70) | PPARDPPARA | |
| SCHEMBL12891111 | 0.85 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL1245382 | 0.84 | PPARD (0.70) | PPARDPPARA | |
| SCHEMBL1245944 | 0.82 | PPARD (0.67) | PPARDPPARA | |
| SCHEMBL1245997 | 0.82 | PPARD (0.67) | PPARDPPARA | |
| SCHEMBL3270859 | 0.82 | PPARD (0.83) | PPARDPPARA | |
| SCHEMBL1245503 | 0.82 | PPARD (0.64) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039841-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2011-02-17 | — | — | US | claimed |
| EP-1763511-B1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-07-28 | — | — | EP | claimed |
| EP-1763511-A1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-21 | — | — | EP | claimed |
| WO-2005105735-A1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | claimed |
| US-20110039841-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2011-02-17 | — | — | US | disclosed |
| US-20110039841-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2011-02-17 | — | — | US | disclosed |
| EP-1763511-B1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1763511-A1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005105735-A1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039841-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.